Who owns PRELUDE THERAPEUTICS INC?
- Ticker: PRLD
- CUSIP Number: 74065p101
Tip: Access positions for across all investors
Analyze quarterly positions in Prelude Therapeutics with up to 7 years of data, all consolidated into one spreadsheet
Download as csv
Download as Excel
Top investors of Prelude Therapeutics stock
Who bought or sold PRELUDE THERAPEUTICS INC this quarter?
| Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
|---|---|---|---|---|---|
| OrbiMed Advisors | 11M | $37M | 0% | Mar 2026 |
|
| Baker Bros. Advisors | 10M | $35M | 0% | Mar 2026 |
|
| Kynam Capital Management | 1.6M | $5.4M | 102% | Mar 2026 |
|
| Vanguard Capital Management | 1.2M | $4.2M | 100% | Mar 2026 |
|
| EcoR1 Capital | 947k | $3.2M | 100% | Mar 2026 |
|
| Two Sigma Investments | 924k | $3.2M | 17% | Mar 2026 |
|
| Sphera Funds Management | 558k | $1.9M | 355% | Mar 2026 |
|
| Acadian Asset Management | 512k | $1.7M | -5% | Mar 2026 |
|
| Millennium Management | 383k | $1.3M | 153% | Mar 2026 |
|
| Marshall Wace | 359k | $1.2M | 31% | Mar 2026 |
|
| Morgan Stanley | 322k | $1.1M | -4% | Mar 2026 |
|
| BlackRock | 322k | $1.1M | 21% | Mar 2026 |
|
| Geode Capital Management | 303k | $1.0M | 11% | Mar 2026 |
|
| Susquehanna International | 289k | $988k | 71% | Mar 2026 |
|
| Renaissance Technologies | 275k | $941k | 1% | Mar 2026 |
|
| Goldman Sachs Group | 237k | $809k | 101% | Mar 2026 |
|
| Jane Street | 193k | $660k | 74% | Mar 2026 |
|
| Vanguard Fiduciary Trust | 157k | $538k | 100% | Mar 2026 |
|
| ADAR1 Capital Management | 153k | $523k | 100% | Mar 2026 |
|
| State Street Corporation | 138k | $473k | 9% | Mar 2026 |
|
| Citadel Advisors | 124k | $425k | 100% | Mar 2026 |
|
| Connor, Clark & Lunn Investment Management | 109k | $373k | 137% | Mar 2026 |
|
| UBS Group | 65k | $222k | 3374% | Mar 2026 |
|
| Hrt Financial | 59k | $200k | 100% | Mar 2026 |
|
| XTX Topco | 57k | $196k | 14% | Mar 2026 |
|
| Bank of America Corporation | 57k | $193k | 100% | Mar 2026 |
|
| Bridgeway Capital Management | 54k | $183k | 0% | Mar 2026 |
|
| Northern Trust | 50k | $171k | 0% | Mar 2026 |
|
| Colony | 50k | $171k | 0% | Mar 2026 |
|
| Dimensional Fund Advisors | 35k | $120k | 100% | Mar 2026 |
|
| HPM Partners | 33k | $112k | 0% | Mar 2026 |
|
| OMERS Administration Corporation | 33k | $112k | -55% | Mar 2026 |
|
| Prudential Financial | 17k | $60k | 12% | Mar 2026 |
|
| Qube Research & Technologies | 16k | $56k | -24% | Mar 2026 |
|
| Point72 Asset Management | 16k | $56k | -72% | Mar 2026 |
|
| Hsbc Holdings | 14k | $48k | 0% | Mar 2026 |
|
| Diametric Capital | 12k | $41k | 100% | Mar 2026 |
|
| Nine Masts Capital | 12k | $40k | 100% | Mar 2026 |
|
| Graham Capital Management | 11k | $39k | 100% | Mar 2026 |
|
| American Century Companies | 10k | $35k | 100% | Mar 2026 |
|
| Barclays | 8.6k | $29k | 0% | Mar 2026 |
|
| FMR | 6.0k | $21k | -2% | Mar 2026 |
|
| Vanguard Global Advisers | 4.6k | $16k | 100% | Mar 2026 |
|
| Group One Trading | 3.9k | $13k | 681% | Mar 2026 |
|
| SBI Securities | 2.6k | $9.0k | -4% | Mar 2026 |
|
| Royal Bank of Canada | 2.3k | $8.0k | 100% | Mar 2026 |
|
| NISA Investment Advisors | 1.6k | $5.6k | 0% | Mar 2026 |
|
| Pnc Financial Services | 1.2k | $4.0k | 0% | Mar 2026 |
|
| Caldwell Sutter Capital | 1.0k | $3.4k | -50% | Mar 2026 |
|
| CWM | 573.00 | $2.0k | -17% | Mar 2026 |
|
| Fortitude Family Office | 230.00 | $786.991000 | 100% | Mar 2026 |
|
| Bnp Paribas Arbitrage, Snc | 95.00 | $325.004500 | 0% | Mar 2026 |
|
| Optiver Holding B.V. | 20.00 | $68.000000 | 0% | Mar 2026 |
|
| Citigroup | 5.00 | $17.000000 | 100% | Mar 2026 |
|
Who sold out of Prelude Therapeutics?
| Fund or Company Name | Date Sold | Shares Held | Valued At |
|---|---|---|---|
| Two Sigma Advisers | Dec 2025 | 237k | $688k |
| TD Asset Management | Dec 2025 | 161k | $466k |
| Manufacturers Life Insurance Company | Dec 2025 | 71k | $200k |